收费全文 | 2037929篇 |
免费 | 151623篇 |
国内免费 | 13048篇 |
耳鼻咽喉 | 25148篇 |
儿科学 | 62810篇 |
妇产科学 | 51515篇 |
基础医学 | 286848篇 |
口腔科学 | 55179篇 |
临床医学 | 189488篇 |
内科学 | 395536篇 |
皮肤病学 | 42973篇 |
神经病学 | 157773篇 |
特种医学 | 75470篇 |
外国民族医学 | 318篇 |
外科学 | 301417篇 |
综合类 | 65086篇 |
现状与发展 | 33篇 |
一般理论 | 836篇 |
预防医学 | 152626篇 |
眼科学 | 48841篇 |
药学 | 153088篇 |
135篇 | |
中国医学 | 12549篇 |
肿瘤学 | 124931篇 |
2021年 | 24262篇 |
2020年 | 15861篇 |
2019年 | 22312篇 |
2018年 | 29483篇 |
2017年 | 23167篇 |
2016年 | 24722篇 |
2015年 | 29736篇 |
2014年 | 40661篇 |
2013年 | 55015篇 |
2012年 | 77519篇 |
2011年 | 81682篇 |
2010年 | 49111篇 |
2009年 | 44627篇 |
2008年 | 72469篇 |
2007年 | 76577篇 |
2006年 | 76253篇 |
2005年 | 72889篇 |
2004年 | 68869篇 |
2003年 | 65345篇 |
2002年 | 62073篇 |
2001年 | 96465篇 |
2000年 | 97368篇 |
1999年 | 81142篇 |
1998年 | 23836篇 |
1997年 | 21079篇 |
1996年 | 20334篇 |
1995年 | 19615篇 |
1994年 | 17759篇 |
1993年 | 16050篇 |
1992年 | 59168篇 |
1991年 | 56904篇 |
1990年 | 54382篇 |
1989年 | 52110篇 |
1988年 | 47424篇 |
1987年 | 46151篇 |
1986年 | 43437篇 |
1985年 | 41131篇 |
1984年 | 30677篇 |
1983年 | 26064篇 |
1982年 | 15262篇 |
1979年 | 26273篇 |
1978年 | 18356篇 |
1977年 | 15581篇 |
1976年 | 14513篇 |
1975年 | 15063篇 |
1974年 | 18141篇 |
1973年 | 17374篇 |
1972年 | 16055篇 |
1971年 | 14782篇 |
1970年 | 13716篇 |
Background and aims
It is not known whether non alcoholic fatty liver disease (NAFLD) is a risk factor for diabetes in non obese, non centrally-obese subjects. Our aim was to investigate relationships between fatty liver, insulin resistance and a biomarker score for liver fibrosis with incident diabetes at follow up, in subjects who were neither obese nor centrally-obese.Methods and results
As many as 70,303 subjects with a body mass index (BMI) < 25 kg/m2 and without diabetes were followed up for a maximum of 7.9 years. At baseline, fatty liver was identified by liver ultrasound, insulin resistance (IR) by homeostatic model assessment of insulin resistance (HOMA-IR) ≥2.0, and central obesity by waist circumference (waist circumference ≥90 cm (men) and ≥85 cm (women). The Fibrosis-4 (FIB-4 score) was used to estimate extent of liver fibrosis. Cox proportional hazards models adjusted for confounders were used to estimate hazard ratios (aHRs) for incident diabetes. As many as 852 incident cases of diabetes occurred during follow up (median [IQR] 3.71 [2.03] years). Mean ± SD BMI was 22.8 ± 1.8 and 21.7 ± 2.0 kg/m2 in subjects with and without diabetes at follow up. In subjects without central obesity and with fatty liver, aHRs (95% CI) for incident diabetes at follow up were 2.17 (1.56, 3.03) for men, and 2.86 (1.50,5.46) for women. Similar aHRs for incident diabetes occurred with fatty liver, IR and the highest quartile of FIB-4 combined, in men; and there was a non significant trend toward increased risk in women.Conclusions
In normal weight, non-centrally obese subjects NAFLD is an independent risk factor for incident diabetes. 相似文献Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge.
Results: Overall, mortality (16.2% vs. 5.3%; p?<?.01), median hospital LOS (42.0 vs. 26.0 days; p?<?.01) and median total costs ($173,144 vs. $98,982; p?<?.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups.
Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT. 相似文献